Lisa Abaid
Gynecologic Oncology · Newport Beach, CANPI 1295943132
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,700 of the $13,268 with a category attached, or 65.6%. GSK accounts for 65.8% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $4,625, more than ten times the $160 reported in 2019.
Across 18 payments — averaging $737.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$9K
- Intuitive Surgical$4K
- Baxter Healthcare$113
- AstraZeneca$66
- Biosense Webster, Inc.$21
- Merck$20
- plus $16 from 2 others
Across 1 payment — averaging $8323.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$8K
What the payments were for
- Consulting fees$8,70066%
- Food & beverage$5684%
- Education$4,00130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 4 | $8,737 |
| Intuitive Surgical | 5 | $4,295 |
| Baxter Healthcare | 1 | $113 |
| AstraZeneca | 4 | $66 |
| Biosense Webster, Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Medtronic | 1 | $16 |
| Clovis Oncology, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SHINGRIX$8,700
- Da Vinci Surgical System$4,233
- TISSEEL$113
How this compares
$13,268 in reported general payments places this provider in the 75th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 16 | $203,876 |
| Estradiol | 26 | $1,130 |
| Letrozole | 12 | $103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $66 | $203,87616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 152 gynecologic oncology providers in California.
Other gynecologic oncology in Newport Beach
- Alberto MendivilNewport Beach$68K
- John BrownNewport Beach$6K
- Tiffany BeckNewport Beach$5K
- John ChanSan Francisco$2M
- Dana ChaseLos Angeles$1.3M
- Ramez EskanderEncinitas$706K
- Krishnansu TewariOrange$495K
- Fabio CappucciniOrange$313K
- Mehdi Moslemi-KebriaUpland$225K
- Amer KaramStanford$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.